永太科技(002326) - 2024 Q1 - 季度财报

Financial Performance - Total revenue for the current period was ¥821,748,310.47, down 18.31% from ¥1,005,914,813.82 year-over-year[27]. - Operating income decreased to ¥33,412,387.14 from ¥42,637,858.31, a decline of 21.5%[20]. - Net profit attributable to shareholders decreased by 22.91% to ¥19,505,595.70 compared to ¥25,302,343.08 in the previous period[27]. - Basic and diluted earnings per share decreased to ¥0.021 from ¥0.029, a drop of 27.59%[27]. - The company reported a 49.90% increase in net profit after deducting non-recurring gains and losses, reaching ¥14,311,964.23 compared to ¥9,547,719.53 last year[27]. - The total comprehensive income for the period was ¥37,330,260.66, compared to ¥16,301,322.14 in the previous period[20]. Assets and Liabilities - The company’s total current assets decreased to ¥3.48 billion from ¥3.80 billion, reflecting a decline of approximately 8%[15]. - Total assets decreased by 2.88% to ¥11,075,463,011.25 from ¥11,404,306,777.82[27]. - Non-current assets totaled RMB 7,591,928,264.45, slightly down from RMB 7,608,372,586.09, indicating a decrease of about 0.22%[41]. - The company's fixed assets increased from RMB 3,554,687,028.57 to RMB 4,022,049,126.17, representing a growth of approximately 13.14%[41]. - Short-term borrowings rose from RMB 1,701,718,161.88 to RMB 1,834,981,388.68, an increase of about 7.73%[41]. - The total liabilities decreased from RMB 8,025,423,047.79 to RMB 7,657,468,929.10, a reduction of approximately 4.58%[42]. - The long-term borrowings decreased from RMB 1,562,568,363.63 to RMB 1,419,118,957.22, indicating a reduction of about 9.15%[42]. Cash Flow - The net cash flow from operating activities was negative at -¥151,481,243.16, a significant decline of 200.26% compared to the previous period[27]. - Cash and cash equivalents at the end of the period were ¥369,932,854.76, down from ¥446,005,890.49 at the beginning of the period[47]. - Investment activities generated a net cash flow of -¥153,166,683.27, an improvement from -¥493,809,492.49 in the previous period[47]. - Financing activities generated a net cash flow of ¥134,699,899.82, down from ¥357,826,763.06 in the previous period[47]. Expenses - Research and development expenses decreased by 37.50%, indicating a reduction in investment in high-tech research[8]. - Research and development expenses decreased to ¥22,213,224.82 from ¥35,541,342.31, reflecting a 37.5% reduction[46]. - The company experienced a decrease in sales expenses to ¥21,957,250.93 from ¥22,186,887.80, a decline of 1.03%[46]. - The company’s financial expenses decreased by 38.39%, primarily due to changes in the exchange rate impacting foreign currency transactions[8]. Other Key Developments - The company signed a material procurement supplementary agreement with CATL on January 9, 2024, indicating ongoing collaboration in the supply chain[14]. - The company received FDA approval for the abbreviated new drug application for fenofibrate capsules on February 2, 2024, marking a significant milestone in product development[14]. - The company plans to dissolve its subsidiary Chongqing Yongyuan Sheng Technology Co., Ltd., as approved in the board meeting on March 19, 2024[14]. - The company’s other comprehensive income increased by 57.67%, attributed to foreign currency translation differences[8]. - Other comprehensive income after tax increased significantly to ¥17,202,412.59 from -¥674,117.90[20].